Acumen director granted RSUs and stock options

Acumen Pharmaceuticals director Jeffrey L. Ives received new equity awards as part of his compensation.

Rhea-AI Filing Summary

Acumen Pharmaceuticals director Jeffrey L. Ives received new equity awards as part of his compensation. He was granted 35,500 restricted stock units, each convertible into one share of common stock, and a stock option covering 53,250 shares at an exercise price of $2.29 per share.

The RSUs and the option will vest in full on the earlier of the first anniversary of the June 3, 2026 grant date or the company’s 2027 annual stockholder meeting, as long as he remains in continuous service. After the RSU grant, he directly holds 48,300 shares of common stock.

Insider Trade Summary

Grant/Award: 88,750 shares

Grant/Award 2 txns

Insider Ives Jeffrey L.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	53,250	$0.00	$0.00
Grant/Award	Common Stock	35,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 53,250 contracts (Direct); Common Stock — 48,300 shares (Direct)

Footnotes (2)

1. F1. Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
2. F2. The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

RSU grant: 35,500 units Option grant size: 53,250 shares Option exercise price: $2.29/share +2 more

5 metrics

RSU grant 35,500 units Restricted stock units awarded to director Jeffrey L. Ives

Option grant size 53,250 shares Stock option covering common stock

Option exercise price $2.29/share Conversion or exercise price for stock option

Option expiration June 3, 2036 Expiration date of stock option grant

Shares held after RSU grant 48,300 shares Common stock directly held following non-derivative transaction

Key Terms

restricted stock unit ("RSU"), contingent right, Stock Option (right to buy), continuous service, +1 more

5 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share"

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

Stock Option (right to buy) financial

"Stock Option (right to buy)"

continuous service financial

"subject to the Reporting Person's continuous service through such vesting date."

annual stockholder meeting financial

"on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting"

An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Acumen Pharmaceuticals (ABOS) director Jeffrey Ives receive?

Jeffrey Ives received 35,500 restricted stock units and a stock option for 53,250 shares of Acumen Pharmaceuticals common stock. The option has a $2.29 exercise price and, like the RSUs, vests in full on the earlier of one year from grant or the 2027 annual meeting.

When do Jeffrey Ives’ new Acumen Pharmaceuticals (ABOS) RSUs vest?

The 35,500 RSUs granted to Jeffrey Ives vest in full on the earlier of the first anniversary of the June 3, 2026 grant date or the 2027 annual stockholder meeting. Vesting requires his continuous service with Acumen Pharmaceuticals through that vesting date.

What are the key terms of Jeffrey Ives’ new Acumen Pharmaceuticals (ABOS) stock option?

Jeffrey Ives received a stock option for 53,250 shares of Acumen Pharmaceuticals common stock at a $2.29 exercise price. The option vests in full on the earlier of one year from June 3, 2026 or the 2027 annual stockholder meeting and expires on June 3, 2036.

How many Acumen Pharmaceuticals (ABOS) shares does Jeffrey Ives hold after the new RSU grant?

Following the grant, Jeffrey Ives directly holds 48,300 shares of Acumen Pharmaceuticals common stock. This reflects his position after receiving 35,500 restricted stock units, which each represent a contingent right to receive one share upon vesting and settlement.

Are Jeffrey Ives’ new Acumen Pharmaceuticals (ABOS) equity awards tied to continued service?

Yes. Both the 35,500 RSUs and the option for 53,250 shares will vest only if Jeffrey Ives maintains continuous service with Acumen Pharmaceuticals through the earlier of the first anniversary of grant or the 2027 annual stockholder meeting, as specified in the award terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:29 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ives Jeffrey L.

(Last) (First) (Middle)

C/O ACUMEN PHARMACEUTICALS, INC.

1210-1220 WASHINGTON STREET, SUITE 210

(Street)

NEWTON MASSACHUSETTS 02465

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acumen Pharmaceuticals, Inc. [ ABOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/03/2026		A		35,500(1)	A	$0	48,300	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.29	06/03/2026		A		53,250		(2)	06/03/2036	Common Stock	53,250	$0	53,250	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

2. The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

	/s/ Derek Meisner, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)